naproxen has been researched along with cyclin d1 in 1 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeCastro, A; Janakiram, NB; Lee, HJ; Paul, S; Rao, CV; Reddy, BS; Simi, B; Smolarek, AK; So, JY; Steele, V; Suh, N; Wang, CX | 1 |
1 other study(ies) available for naproxen and cyclin d1
| Article | Year |
|---|---|
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Azoxymethane; beta Catenin; Carcinogens; Colonic Neoplasms; Cyclin D1; eIF-2 Kinase; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunoenzyme Techniques; Interleukin-4; Male; Naproxen; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Inbred F344; Signal Transduction; Sulindac; Tumor Necrosis Factor-alpha | 2011 |